E!115376 REPRINT, Asgard Therapeutics AB
| Reference number | |
| Coordinator | Asgard Therapeutics AB |
| Funding from Vinnova | SEK 4 952 330 |
| Project duration | October 2021 - September 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
We have successfully met our project goals. We optimized and validated viral vector constructs, showing the ability of AT-108 to transduce and reprogram cancer cells into dendritic cells both in vitro and in vivo. Notably, we observed a complete anti-tumor response and long-term memory, with early safety studies showing a strong safety profile. Published in Science, these proof-of-principle results also helped us raise €30 million to fund further development and prepare for FIH clinical trial.
Expected long term effects
The project is expected to have significant long-term effects by advancing cellular reprogramming to potentially lower cancer mortality rates. The established collaborations and networks will drive future research and innovation, while the €30 million Series A funding accelerates AT-108´s path toward clinical trials.
Approach and implementation
The project was executed as planned, with a smooth implementation that aligned with our goals. It developed as intended, closely following the timeline without external influences or unexpected events. Collaboration among team members and partners was effective, enhancing our ability to achieve objectives. Overall, the project was a success, paving the way for future advancements in cancer treatment.